Stock listing
BOATS:BDTX Black Diamond Therapeutics, Inc. Stock
US listing (BOATS) of Black Diamond Therapeutics, Inc. · home listing NASDAQ:BDTX
Follow Black Diamond Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:BDTX
$1.75 USD -0.03 (-1.7%)
Close on Nov 2, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BDTX
- Day range
- $1.75 – $1.86 USDNov 2, 2026
- Volume
- 493,685 sharesNov 2, 2026
- Market cap
- $100.5M USDAt the close on Nov 2, 2026 · price × 57.45M shares outstanding
- 52-week range
- $1.60 – $4.94 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $1.33M USDMedian day 599,900 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BDTX · Home | $1.75 USD | -0.03 (-1.7%) | 493,685 | $1.79 | $1.86 | $1.75 | $1.78 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:BDTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.75 | -0.03 | -1.7% | $1.79 | $1.86 | $1.75 | 493,685 | |
| $1.78 | -0.08 | -4.3% | $1.86 | $1.90 | $1.76 | 515,418 | |
| $1.86 | +0.03 | +1.6% | $1.85 | $1.89 | $1.795 | 548,804 | |
| $1.83 | +0.08 | +4.6% | $1.74 | $1.87 | $1.705 | 1,043,391 | |
| $1.75 | +0.06 | +3.6% | $1.71 | $1.77 | $1.645 | 1,099,234 | |
| $1.69 | -0.19 | -10.1% | $1.90 | $1.90 | $1.67 | 861,132 | |
| $1.88 | -0.20 | -9.6% | $2.05 | $2.05 | $1.83 | 927,726 | |
| $2.08 | 0.00 | 0.0% | $2.06 | $2.105 | $2.03 | 790,955 | |
| $2.08 | +0.01 | +0.5% | $2.07 | $2.14 | $2.005 | 2,355,483 | |
| $2.07 | +0.26 | +14.4% | $1.82 | $2.14 | $1.82 | 2,113,789 | |
| $1.81 | +0.09 | +5.2% | $1.71 | $1.835 | $1.71 | 825,582 | |
| $1.72 | -0.02 | -1.1% | $1.75 | $1.75 | $1.675 | 539,800 | |
| $1.74 | +0.04 | +2.4% | $1.69 | $1.74 | $1.67 | 624,700 | |
| $1.70 | +0.02 | +1.2% | $1.67 | $1.76 | $1.63 | 1,069,400 | |
| $1.68 | -0.09 | -5.1% | $1.76 | $1.77 | $1.60 | 1,141,000 | |
| $1.77 | -0.06 | -3.3% | $1.865 | $1.865 | $1.765 | 377,700 | |
| $1.83 | +0.02 | +1.1% | $1.81 | $1.83 | $1.79 | 448,800 | |
| $1.81 | -0.02 | -1.1% | $1.81 | $1.81 | $1.77 | 785,000 | |
| $1.83 | +0.03 | +1.7% | $1.79 | $1.87 | $1.775 | 563,300 | |
| $1.80 | -0.14 | -7.2% | $1.94 | $1.96 | $1.795 | 839,100 | |
| $1.94 | +0.05 | +2.6% | $1.90 | $1.95 | $1.875 | 838,600 | |
| $1.89 | +0.01 | +0.5% | $1.91 | $1.94 | $1.875 | 472,200 | |
| $1.88 | -0.005 | -0.3% | $1.88 | $1.90 | $1.84 | 399,100 | |
| $1.885 | +0.015 | +0.8% | $1.89 | $1.93 | $1.845 | 551,800 | |
| $1.87 | +0.04 | +2.2% | $1.84 | $1.89 | $1.825 | 440,200 | |
| $1.83 | -0.05 | -2.7% | $1.89 | $1.89 | $1.81 | 648,300 | |
| $1.88 | -0.01 | -0.5% | $1.91 | $1.915 | $1.85 | 378,300 | |
| $1.89 | -0.01 | -0.5% | $1.90 | $1.915 | $1.83 | 459,700 | |
| $1.90 | -0.08 | -4.0% | $1.97 | $1.97 | $1.85 | 613,500 | |
| $1.98 | +0.03 | +1.5% | $1.93 | $1.995 | $1.90 | 743,900 | |
| $1.95 | -0.01 | -0.5% | $1.96 | $1.97 | $1.91 | 827,100 | |
| $1.96 | +0.03 | +1.6% | $1.91 | $1.96 | $1.91 | 1,178,500 | |
| $1.93 | -0.01 | -0.5% | $1.98 | $2.02 | $1.92 | 665,300 | |
| $1.94 | -0.03 | -1.5% | $1.97 | $2.007 | $1.915 | 733,900 | |
| $1.97 | -0.06 | -3.0% | $2.02 | $2.02 | $1.94 | 301,800 | |
| $2.03 | +0.05 | +2.5% | $1.98 | $2.04 | $1.97 | 514,100 | |
| $1.98 | +0.02 | +1.0% | $1.99 | $2.00 | $1.94 | 589,100 | |
| $1.96 | -0.14 | -6.7% | $2.06 | $2.06 | $1.92 | 676,100 | |
| $2.10 | 0.00 | 0.0% | $2.09 | $2.149 | $2.065 | 402,400 | |
| $2.10 | -0.02 | -0.9% | $2.09 | $2.13 | $2.072 | 367,200 | |
| $2.12 | +0.02 | +1.0% | $2.08 | $2.145 | $2.061 | 323,700 | |
| $2.10 | -0.04 | -1.9% | $2.15 | $2.166 | $2.06 | 609,800 | |
| $2.14 | +0.10 | +4.9% | $2.08 | $2.155 | $2.05 | 561,300 | |
| $2.04 | -0.06 | -2.9% | $2.09 | $2.11 | $2.02 | 759,100 | |
| $2.10 | -0.13 | -5.8% | $2.22 | $2.225 | $2.10 | 507,000 | |
| $2.23 | -0.04 | -1.8% | $2.28 | $2.29 | $2.17 | 521,900 | |
| $2.27 | 0.00 | 0.0% | $2.26 | $2.32 | $2.24 | 457,600 | |
| $2.27 | +0.03 | +1.3% | $2.21 | $2.29 | $2.16 | 491,300 | |
| $2.24 | +0.085 | +3.9% | $2.19 | $2.245 | $2.185 | 417,500 | |
| $2.155 | -0.055 | -2.5% | $2.22 | $2.22 | $2.13 | 345,000 | |
| $2.21 | +0.06 | +2.8% | $2.15 | $2.26 | $2.15 | 656,600 | |
| $2.15 | -0.04 | -1.8% | $2.17 | $2.19 | $2.08 | 1,137,800 | |
| $2.19 | +0.13 | +6.3% | $2.08 | $2.21 | $2.08 | 827,000 | |
| $2.06 | +0.01 | +0.5% | $2.05 | $2.08 | $2.02 | 474,800 | |
| $2.05 | +0.03 | +1.5% | $2.01 | $2.085 | $2.01 | 389,800 | |
| $2.02 | 0.00 | 0.0% | $2.01 | $2.045 | $1.96 | 330,400 | |
| $2.02 | -0.08 | -3.8% | $2.12 | $2.12 | $2.00 | 489,100 | |
| $2.10 | +0.01 | +0.5% | $2.12 | $2.14 | $2.02 | 645,500 | |
| $2.09 | +0.11 | +5.6% | $2.01 | $2.10 | $1.95 | 812,700 | |
| $1.98 | +0.03 | +1.5% | $1.95 | $2.02 | $1.93 | 664,900 | |
| $1.95 | +0.03 | +1.6% | $1.94 | $1.985 | $1.905 | 599,900 | |
| $1.92 | +0.13 | +7.3% | $1.80 | $1.935 | $1.76 | 748,100 | |
| $1.79 | +0.01 | +0.6% | $1.77 | $1.825 | $1.76 | 384,200 | |
| $1.78 | +0.045 | +2.6% | $1.80 | $1.82 | $1.735 | 917,200 | |
| $1.735 | +0.045 | +2.7% | $1.73 | $1.75 | $1.675 | 429,300 |
- Ticker
- BOATS:BDTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Sep 2, 2026
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Latest deck · Dec 3, 2025
Corporate Update (December 2025)
Corporate update · 38 slides
Latest news
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Sep 2, 2026
Closed $2.10 (-1.9%) on Sep 3, 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 5, 2026
Closed $1.92 (+7.3%) on Aug 6, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
Closed $2.28 (-35.8%) on May 22, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
Closed $3.00 (+16.3%) on May 19, 2026
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Closed $2.72 (-3.5%) on May 7, 2026
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Apr 21, 2026
Closed $3.15 (+3.3%) on Apr 21, 2026
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 16, 2026
Closed $2.23 (+1.8%) on Mar 17, 2026
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Jan 28, 2026
Closed $2.57 (-0.8%) on Jan 28, 2026
Issued by another party
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Dec 3, 2025
Closed $2.69 (-22.0%) on Dec 3, 2025
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Dec 2, 2025
Closed $2.69 (-22.0%) on Dec 3, 2025
Decks
Corporate Update (December 2025)
Corporate update · 38 slides · Dec 3, 2025
Investor Presentation (March 2025)
Investor deck · 38 slides · Mar 19, 2025
AACR Annual Meeting 2024
Conference · 15 slides · Apr 5, 2024
Investor Presentation (January 2024)
Investor deck · 42 slides · Jan 4, 2024
Black Diamond Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 97 in all · newest Sep 2, 2026 · oldest 2020
- Decks
- 7 decks · latest Dec 3, 2025
Where Black Diamond Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BDTX · Home listing | NASDAQ | United States | USD |
| BOATS:BDTX · This page | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Black Diamond Therapeutics, Inc.